Connect with us

Hi, what are you looking for?

Jewish Business News


Mori Arkin in talks to acquire Sol-Gel


Sol-Gel is trying to improve acne and rosacea treatments using nanoscale particles.


Mori Arkin

Businessman Mori Arkin is in advanced talks to buy Sol-Gel, which is developing skincare products using nanotechnology, sources inform “Globes.” If the deal goes through, Arkin will pay $10 million, or more, if milestones are met. The company has confirmed the report.

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at
Thank you.

Sol-Gel, managed by Dr. Alon Seri-Levy, has developed a method of wrapping molecules with nanoscale particles in order to help the materials inside penetrate the skin. While the active ingredients in Sol-Gel are mostly generic, the wrapping is unique technology, which is meant to improve the performance of the drug.

The company’s lead products are a treatment of the skin condition rosacea, which has completed Phase II clinical trials, and an acne treatment, which is about to begin Phase II trials.

Sol-Gel is a veteran company, which was established in 1997. Since its founding, $26 million has been invested by leading Israeli and foreign venture capital firms, including Argonaut,  Challenge Fund – Etgar, andJerusalem Venture Partners (JVP). In 2008, the company had a “mini-exit, ” when it sold some of its sun-protection technology to Merck & Co. for $10 million.

The investors did not cash out of the company, but instead invested in the product portfolio, in an attempt to reach a larger exit. However, the funds that invested in Sol-Gel have reached the end of their investment period, and are currently considering accepting Arkin’s offer.

The rosacea product completed Phase II clinical trials in 2012, but the company did not find a suitable partner with whom to proceed to Phase III, or the funding to enable it to lead the process along. The product is a substance called benzoyl peroxide, which is currently used to treat acne, not rosacea, because the medicine itself causes skin irritation in rosacea sufferers. The version with Sol-Gel’s wrapper, which enables extended release of the drug, is meant to make it suitable for these patients as well.

Similar developments

Sol-Gel conducted negotiations to register its product with a few leading companies in recent years, including a deal that was meant to yield $150 million for the company if the product succeeded. However, the corporation with which the company negotiated decided that the product was still in too early a stage of development. If the product develops and the deal with the corporation is signed, Sol-Gel will receive an additional $7 million from Arkin.

Mori Arkin is a member of the family that founded Agis, which was also active in the field of dermatology. Arkin led the company to its sale to Perrigo Company (NYSE:PRGO; TASE:PRGO) for $900 million in cash and shares, and has been investing in biomed and other fields since that time (including an investment in Bezeq Israeli Telecommunication Co. Ltd. (TASE: BEZQ)).

Arkin Holdings is currently amassing various technologies in the field of dermatological R&D, and has invested in Foamix, which is also developing treatments for rosacea and acne, but with a different, foam-based delivery method. In response to the question of why he chose to invest in two companies with similar developments, Arkin said, “There are enough zits for everyone.”

Published by Globes [online], Israel business news – 



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The Movie The Professional is what made Natalie Portman a Lolita.


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.

Copyright © 2021 Jewish Business News